---
trial_id: 1863
discovery_date: 2022-09-27 13:01:52.630074
date: 2022-09-27 13:01:52.630074
title: "An open-label, adaptive design study in patients with amyotrophic lateral sclerosis (ALS) to characterize safety, tolerability and brain microglia response, as measured by TSPO binding, following m..."
summary: |
  <p>EudraCT Number: 2019-000826-22<br />Sponsor Protocol Number: CBLZ945C12201<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2019-09-17<br />Medical condition: Amyotrophic lateral sclerosis (ALS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10002026<br />Term: Amyotrophic lateral sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000826-22/SE">SE</a> (Restarted), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000826-22/FI">FI</a> (Restarted)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000826-22'
published_date: NaT
trial_source: 
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2019-000826-22<br />Sponsor Protocol Number: CBLZ945C12201<br />Sponsor Name: Novartis Pharma AG<br />Start Date: 2019-09-17<br />Medical condition: Amyotrophic lateral sclerosis (ALS)<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10002026<br />Term: Amyotrophic lateral sclerosis<br />Level: PT<br /><br />Population Age: Adults, Elderly<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000826-22/SE">SE</a> (Restarted), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000826-22/FI">FI</a> (Restarted)</p>